Dual GLP-1/glucagon receptor agonist developed for obesity and NASH. Glucagon component increases energy expenditure and hepatic fat oxidation while GLP-1 suppresses appetite. Particularly effective for reducing liver fat content.
Inject SubQ once weekly. Titrate: 0.5mg x4wk → 1mg x4wk → 2.4mg x4wk → 4.8mg x4wk → 6mg. Monitor liver enzymes.
Log doses, calculate reconstitution, set reminders, and get AI guidance for Survodutide.
Start Free Trial